Melane Sampson, Author at BioTuesdays

Developments

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

In a presentation at the Society for Neuroscience 2021 meeting, Ben Land, Ph.D., research assistant professor at the University of Washington’s Department of Pharmacology, reported additional positive data from an...

November 8, 2021

Developments

TransMedics posts positive results from randomized OCS DCD heart trial

TransMedics Group (NASDAQ:TMDX) reported positive topline results from its OCS donors after circulatory death (DCD) heart trial. The OCS DCD heart trial was designed as the first and only randomized trial to compare...

November 4, 2021

Developments

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Closely held Activ Surgical, a digital surgery pioneer, completed of its first-in-human surgery clinical trial utilizing the company’s technology-as-a-service bundle: the ActivInsights augment reality (AR)-based...

November 3, 2021

Developments

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

Top-line data from Clene’s RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS), failed to meet the primary or...

November 2, 2021

Developments

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

Sio Gene Therapies (NASDAQ:SIOX) received fast track designation for AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease...

November 1, 2021

Developments

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Radiopharmaceuticals developer, POINT Biopharma Global (NASDAQ:PNT), and Kinectrics entered into a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a...

October 29, 2021

Developments

Kezar doses first patient in advanced solid tumor malignancies study

Kezar Life Sciences (NASDAQ:KZR) dosed the first patient in a Phase 1 clinical trial evaluating KZR-261, a broad-spectrum, anti-tumor agent that acts through direct interaction and inhibition of the Sec61 translocon...

October 27, 2021

Developments

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

Altamira Therapeutics (NASDAQ:CYTO) signed a letter of understanding (LOU) with Singapore’s Wellesta Holdings for the marketing and distribution of Bentrio, its nasal spray for protection against airborne viruses and...

October 25, 2021

Developments

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

Titan Pharmaceuticals (NASDAQ:TTNP) has received funding from the Bill & Melinda Gates Foundation to support its ability to deliver a human immunodeficiency virus (HIV) preventative therapeutic and a contraceptive...

October 25, 2021

Developments

PharmaJet, WHO, Gates Foundation in Somalia polio vaccination campaign

Closely held PharmaJet’s Tropis intradermal needle-free injection system is being used in a campaign in Somalia, delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in...

October 21, 2021

Author - Melane Sampson

Sustained anti-pruritic effect of Titan’s TP-2021 implant featured at Neuroscience conference

TransMedics posts positive results from randomized OCS DCD heart trial

Activ Surgical completes first In-human study of surgical intelligence and sensing platform

Clene fails to meet endpoints in Phase 2 RESCUE-ALS clinical trial

FDA grants Sio Gene fast track for gene therapy for GM2 gangliosidosis

POINT Biopharma, Kinectrics in Yb-176 supply agreement for NA production of n.c.a. Lu-177

Kezar doses first patient in advanced solid tumor malignancies study

Altamira, Wellesta in LOU to distribute Bentrio in 6 key Asian markets

Titan Pharma receives funding from Gates Foundation for combination HIV therapeutic and contraceptive implant for women in developing countries

PharmaJet, WHO, Gates Foundation in Somalia polio vaccination campaign

Subscribe